{"filings":[{"id":2078997,"accession_number":"0001493152-26-036170","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2026-08-05T20:10:53+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeMD Q2 revenue $47.3M, adjusted EBITDA loss $3.5M; revises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $47.3M within guidance; adjusted EBITDA loss $3.5M improved 21% sequentially but below guided range.","Gross margin expanded ~280 bps YoY to ~89%; total active subscribers up 20% YoY to ~356k.","Weight management subscribers ~108k; ~95% of new weight patients start on branded GLP-1 therapies.","Launched telehealth co-marketing with Halozyme's Antares for XYOSTED; expects $2-3M net launch costs in 2026.","Revises FY2026 guidance: revenue $205.5M-$212.5M, adjusted EBITDA -$6M to breakeven; expects positive adjusted EBITDA in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1177476,"accession_number":"0001493152-26-029503","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2026-06-22T12:25:56+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD partners with Halozyme for exclusive telehealth co-marketing of XYOSTED, launching July 2026 in 37 states","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.","Program launches July 2026; initially available in 37 states with a transparent $249/month all-inclusive price.","LifeMD's affiliated medical group will evaluate patients, and its pharmacy will be the preferred dispensing pharmacy.","Three-year initial term with automatic renewal; either party can terminate if co-marketing budget missed for two consecutive quarters.","Companies will jointly invest in consumer education and promotional initiatives to expand awareness of hypogonadism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99970,"accession_number":"0001493152-26-021520","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeMD Q1 revenue $50.2M beats guidance; adds 42k subscribers, record GLP-1 signups","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $50.2M vs guidance $48-49M; adj. EBITDA loss $4.5M in line.","Gross margin 88% (up ~420 bps YoY) on favorable mix & lower fulfillment costs.","Record GLP-1 new-patient revenues up ~120% QoQ; Women's Health signups up 657% QoQ with 70% lower CAC.","Subscribers exceeded 365k, net adds of 42k in Q1 (largest quarterly net addition).","Affirmed FY2026 revenue guidance $220-230M, adj. EBITDA $12-17M; cash $34.5M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":50162956.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116283,"accession_number":"0001493152-26-011228","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints new CFO, promotes CBO and CMO; outgoing CFO to advise","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Marc Benathen resigns effective March 31, 2026; will provide advisory services for 6–12 months at $38,117/month.","Atul Kavthekar appointed CFO effective March 16, 2026; base salary $500,000, target bonus 50%, 675,000 RSU grant.","Jessica Friedeman promoted to Chief Business Officer to lead enterprise and employer health offerings.","Chris Pisano appointed Chief Marketing Officer; 25+ years marketing experience, oversees brand and digital strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116282,"accession_number":"0001493152-26-009380","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).","Q4 2025 revenue $46.9M (+4% YoY); adjusted EBITDA $4.8M (+348% YoY).","Launched oral Wegovy post-year-end; >80% of new weight management patients using branded therapy; Q1 sign-ups at record levels.","Ended 2025 with $36.8M cash, no debt; guides to annualized revenue >$250M and adj EBITDA >$25M by Q4 2026.","Benefits infrastructure on track to cover ~220M Americans in Q2 2026; women's health seeing strong early growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116281,"accession_number":"0001493152-26-000525","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"LifeMD closes $50M revolving credit facility with Citizens Bank, N.A.","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facility provides $30M committed plus $20M accordion; maturity January 2, 2029.","No amount drawn at closing; Company cites sufficient cash flow for organic growth.","Interest based on Term SOFR + 1.50%-2.25% or ABR + 0.50%-1.25%; commitment fee 0.225%-0.30%.","No upfront fee; credit supports corporate development and shareholder value initiatives.","Financial covenants: leverage ratio ≤2.50x, interest coverage ≥3.00x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132744,"accession_number":"0001493152-25-023853","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeMD Q3 revenue $60.2M (+13%), adj EBITDA $5.1M; paid off debt, sold WorkSimpli","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $60.2M (+13% YoY); adjusted EBITDA $5.1M (+20% YoY).","Telehealth revenue $47.3M (+18% YoY); telehealth adjusted EBITDA $2.9M (+30% YoY).","Paid off all outstanding debt in Q3; divested majority stake in WorkSimpli after quarter end.","Pennsylvania 503-A compounding pharmacy approved; licensed in 14 states, pursuing 50-state license.","RexMD added nearly 10,000 net new subscribers; strong early traction in behavioral, women's, men's health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":186975039.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132743,"accession_number":"0001493152-25-020913","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD delays Q3 earnings, expects late 10-Q filing due to $4.6M revenue recognition corrections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2025 earnings rescheduled to Nov 17, 2025; expects to file Form 12b-25 for late 10-Q.","Rev rec errors for periods ended Dec 31, 2023, Dec 31, 2024, and Jun 30, 2025; cumulative $4.6M (1.4% of cumulative revenue).","Adjustments do not materially impact reported revenue vs. guidance; no effect on cash flow or cash position.","Company's auditors have not completed review; adjustments may change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132742,"accession_number":"0001493152-25-020713","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"LifeMD sells majority stake in WorkSimpli for $65M enterprise value; receives $22M cash at close","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 80% of WorkSimpli units to buyer group led by founder/CEO; enterprise value ~$65M.","LifeMD received ~$22M cash at close (91.6% of $24M base price) for its 73.3% pre-sale ownership.","Sellers eligible for up to $28M additional cash if WorkSimpli meets growth/operational targets over 3 years.","LifeMD expects to use NOL carryforwards to offset most capital gains from the sale.","Transaction positions LifeMD as pure-play virtual care and pharmacy; plans cardiometabolic expansion in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149277,"accession_number":"0001493152-25-012214","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"LifeMD dismisses CBIZ CPAs, appoints PwC; cites material weaknesses in internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 15, 2025, LifeMD dismissed CBIZ CPAs (appointed Apr 24, 2025) as auditor; no disagreements.","Reportable events: material weaknesses in ITGCs (user access, change management, SOC reports) and business process controls (IPE, review).","On Aug 18, 2025, Audit Committee appointed PricewaterhouseCoopers LLP as independent auditor for FY2025.","No prior consultations with PwC on accounting principles or audit opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149276,"accession_number":"0001641172-25-022258","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeMD Q2 revenue up 23% to $62.2M, adjusted EBITDA up 223% to $7.1M; revises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $62.2M (+23% YoY), telehealth revenue $48.6M (+30%); telehealth adjusted EBITDA $3.4M (+560%).","Adjusted EBITDA $7.1M (+223% YoY); generated >$8M operating cash flow.","Paid down $2.1M senior debt, ended quarter with $36.2M cash; fully repaid all senior debt post-quarter.","Launched nationwide behavioral health offering, acquired virtual women's health brand, upgraded LifeMD+ membership.","Revised FY2025 guidance downward due to temporary challenges at Rex MD, still expects strong YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":127915941.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149275,"accession_number":"0001493152-25-011523","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints Shayna Webb Dray as COO; promotes two other executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment of Shayna Webb Dray as COO effective March 27, 2025; base salary $400K, 100,000 RSUs with time and performance vesting.","Jessica Friedeman promoted to Chief Marketing and Product Officer, expanding role to include product oversight.","Jacob Ellison promoted to Chief Analytics Officer, overseeing data strategy, AI, and FP&A.","Ms. Webb Dray previously SVP Operations; led launch and scaling of weight management program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168305,"accession_number":"0001641172-25-015270","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeMD shareholders elect seven directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors: Justin Schreiber, Dr. Joseph DiTrolio, Roberto Simon, John Strawn, Dr. Joan LaRovere, William Febbo, Dr. Calum MacRae.","All director candidates received 'for' votes ranging from 16.8M to 21.6M; broker non-votes ~9.7M.","Ratified CBIZ CPAs, P.C. as independent auditor for FY 2025 with 31.5M for, 38K against, 179K abstain.","Quorum achieved at annual meeting held June 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168304,"accession_number":"0001641172-25-008841","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeMD Q1 revenue up 49% to $65.7M; first GAAP profit; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $65.7M (+49% YoY); telehealth revenue up 70% to $55.8M.","GAAP net income $0.6M ($0.01 diluted EPS), first-ever positive GAAP EPS.","Adj. EBITDA $8.7M (vs. $0.1M); telehealth adj. EBITDA $5.3M (vs. -$1.3M).","FY 2025 guidance raised: revenue $268-275M, adj. EBITDA $31-33M.","Partnered with LillyDirect/NovoCare for branded GLP-1 access (Zepbound, Wegovy)."],"consensus_eps_estimate":-0.0476,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":65697756.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168303,"accession_number":"0001641172-25-006539","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD acquires Optimal Human Health MD assets for 100k shares; launches women's health vertical","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired key assets from Optimal Human Health MD for 100,000 shares of common stock (50k at close, 50k at 1yr) plus earn-out.","Earn-out: up to 200k additional shares if patient/revenue milestones met (2,500/$2.5M or 5,000/$4.5M).","Dr. Doug Lucas joins LifeMD as VP, Female Health & Clinical Operations under 3-year employment agreement.","At least 75% of Optimal's employees accepted employment offers from LifeMD.","Women's health offering expected Summer 2025; addresses $60-70B market by 2030 per BCG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168302,"accession_number":"0001641172-25-006228","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"LifeMD replaces auditor Marcum with CBIZ; cites material weaknesses in internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed same day.","Prior reports for FY2024 and FY2023 were unqualified with no disagreements on accounting principles.","Reportable events: material weaknesses in ITGCs (user access, change management, SOC report review) and business process controls (IPE and review procedures).","CBIZ had acquired Marcum's attest business on November 1, 2024, prompting the transition.","No consultations with CBIZ prior to engagement on accounting or auditing matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185487,"accession_number":"0001493152-25-009690","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeMD Q4 revenue $64.3M (+43% YoY), adj EBITDA $9.0M; FY2025 rev guidance $265-275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $64.3M (+43% YoY); telehealth revenue $49.9M (+60%); GAAP net loss narrowed to $0.9M from $4.5M.","Adjusted EBITDA $9.0M, up 78% from $5.0M; telehealth adj EBITDA surged 396% to $5.9M.","Telehealth active subscribers 275k (+27% YoY); WorkSimpli subscribers 164k (+3%, sequentially up 3k).","Full-year 2025 guidance: revenue $265-275M, adj EBITDA $30-32M; expects gross margin 88-90%.","Ended 2024 with $35M cash; introduced Q1 2025 guidance rev $61-63M, adj EBITDA $5-7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202077,"accession_number":"0001493152-24-052604","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD raises CEO Justin Schreiber's base salary to $500,000 effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chairman and CEO Justin Schreiber's annual base salary increases from $300,000 to $500,000, effective January 1, 2025.","Salary increase implemented via Second Amendment to Employment Agreement dated December 24, 2024.","All other terms of the prior Employment Agreement, including target bonus and equity grants, remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202076,"accession_number":"0001493152-24-051819","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeMD board member Robert Jindal to resign effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Jindal voluntarily resigned from LifeMD's board, effective December 31, 2024.","Mr. Jindal's resignation is not due to any disagreement with the company's operations, policies, or practices.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202075,"accession_number":"0001493152-24-043097","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeMD director Naveen Bhatia resigns from board effective Oct 25, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Naveen Bhatia voluntarily resigned from LifeMD's board of directors.","Resignation effective October 25, 2024; no disagreement with company operations.","Company thanked Bhatia for his service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238069,"accession_number":"0001493152-24-024278","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LifeMD stockholders approve 3M share increase in 2020 equity plan; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved Third Amended and Restated 2020 Equity Plan, increasing share reserve by 3,000,000 shares (13,225,022 for, 8,347,423 against).","Elected nine directors; Justin Schreiber received highest votes (22,186,275 for), Roberto Simon lowest (15,381,405 for).","Non-binding advisory vote on executive compensation passed: 19,936,967 for, 2,250,462 against.","Ratified Marcum LLP as auditor for FY2024: 29,321,622 for, 288,475 against.","All four proposals passed at June 14, 2024 annual meeting; quorum of 29,831,868 shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238068,"accession_number":"0001493152-24-017571","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints Dr. Calum MacRae, Harvard cardiologist, to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. MacRae appointed as independent director effective April 26, 2024.","He is Vice Chair for Scientific Innovation, Brigham and Women's Hospital, and Harvard professor.","Compensation: 50,000 restricted shares vesting in three annual tranches through 2027.","MacRae's expertise includes cardiology, virtual care, and chronic disease management.","Press release issued April 29, 2024; no other material changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273001,"accession_number":"0001493152-23-044648","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["3.02","7.01","8.01","9.01"],"status":"ready","headline":"LifeMD partners with Medifast, secures $20M investment for weight management collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Medifast invests $20M total: $10M platform support payment and $10M purchase of 1,224,425 LifeMD shares at $8.1671/share.","Collaboration integrates LifeMD's telehealth and GLP-1 offering with Medifast's OPTA VIA coach-guided lifestyle program.","LifeMD issued shares in private placement to Medifast subsidiary; Medifast gets non-voting board observer rights.","Platform support payments: $5M at closing, $2.5M by March 31, 2024, and $2.5M by June 30, 2024 upon milestones.","Companies aim to offer comprehensive weight management solution addressing projected $100B market by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273000,"accession_number":"0001493152-23-041139","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD director Velge resigns; CEO Schreiber receives 100k share equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bertrand Velge resigned from LifeMD board effective Nov 8, 2023; no disagreement with company.","CEO Justin Schreiber entered First Amendment to Employment Agreement on Nov 13, 2023.","Awards: 50,000 restricted shares vesting Jan 1, 2024; conditional grant of 50,000 shares by Nov 13, 2024.","Upon change in control or termination without cause/good reason, 100% of awards vest immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289839,"accession_number":"0001493152-23-027430","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD furnishes investor presentation for August 2023; no specific new figures disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation expected to be used in meetings with investors, analysts, and others starting August 9, 2023.","No financial or operational targets from the presentation are included in the filing text.","Company disclaims any duty to update the presentation; information is furnished, not filed.","Risk factors and forward-looking statements referenced with caution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289838,"accession_number":"0001493152-23-026121","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeMD President Alex Mironov resigns to join Rothschild & Co.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alex Mironov voluntarily resigned as President of LifeMD, effective July 28, 2023.","Mr. Mironov is leaving to become a Managing Director at Rothschild & Co.","Resignation was not due to any disagreement with LifeMD on operations, policies, or practices.","No successor has been named; the company thanked him for his service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289837,"accession_number":"0001493152-23-024593","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD cancels CFO's underwater options; grants 536,250 performance-vested restricted shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Marc Benathen's 200,000 stock options (strike $21.02) and 250,000 performance units cancelled.","New grant: 536,250 restricted shares; 25,000 RSUs accelerated to immediate vest.","Performance milestones: $100M revenue/5% EBITDA margin by 2025; $200M/10% by 2027.","Time-based vesting: 50,000 shares vest Jan 1, 2024; 75,000 on Jan 1, 2025.","All unvested shares vest immediately upon change of control or termination without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289836,"accession_number":"0001493152-23-023977","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeMD reports annual meeting results: directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["At June 16 annual meeting, stockholders elected nine directors: Schreiber, Galluppi, Bhatia, DiTrolio, Simon, Strawn, Velge, Jindal, LaRovere.","Each director received between 11.2M and 13.0M votes for; broker non-votes totaled 7.2M shares.","Ratification of Marcum LLP as independent auditor passed with 20.2M for, 0.3M against, 0.6M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310766,"accession_number":"0001493152-23-022145","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints William Febbo (OptimizeRx CEO) to Board; Galluppi resigns as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stefan Galluppi resigns from Board effective June 20, 2023; no disagreement; continues as Chief Innovation Officer.","William Febbo appointed to Board; receives 75,000 restricted shares (half vest immediately) and 37,500 stock option.","Febbo also entered consulting agreement May 30 for 375,000 restricted shares vesting quarterly through Nov 2024.","Febbo is CEO of OptimizeRx (OPRX) with 25+ years in healthcare and digital health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310765,"accession_number":"0001493152-23-021726","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD grants GC Eric Yecies 375,000 restricted shares with performance milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["375,000 restricted shares granted; replaces 200,000 stock options ($7.55 strike) and 105,000 performance units cancelled.","150,000 shares time-vest: 12,500 immediately, 37,500 Nov 20, 2023, 100,000 Jan 1, 2024.","225,000 performance shares: $100M net revenue/5% EBITDA margin by 2025; $150M/10% by 2026; $200M/10% by 2027.","75,000 shares vest by CEO/Board discretion for 2023 and 2024 performance on 3/1/24 and 3/1/25.","Unvested shares accelerate upon change of control or termination without cause/good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329388,"accession_number":"0001493152-23-008607","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"LifeMD closes $40M senior secured credit facility with Avenue Capital; $15M drawn upfront","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["LifeMD closed $40M senior secured credit facility with Avenue Capital; initial $15M funded at closing.","Interest rate: greater of Prime+4.75% or 12.50%; maturity Oct 1, 2026, with 18-24 month interest-only period.","Issued warrants for 967,742 shares of common stock at $1.24 per share.","Second tranche $5M available in Q4 2023; accordion option for additional $20M subject to mutual approval.","Management states financing strengthens balance sheet and provides sufficient capital for long-term needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329387,"accession_number":"0001493152-23-004330","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints Dr. Joan LaRovere to Board; Kathleen E. Walsh resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Joan LaRovere appointed to LifeMD Board effective Feb 9, 2023; Board now 9 directors, 7 independent.","LaRovere is a Harvard Medical School professor, Boston Children's Hospital physician, and co-founder of Virtue Foundation.","Kathleen E. Walsh resigned from Board effective Feb 9, 2023 to become Secretary of HHS for Massachusetts; no disagreement.","LaRovere received 75,000 restricted shares (half vest immediately) and an option for 37,500 shares; also $6,000 quarterly compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329386,"accession_number":"0001493152-23-004172","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"LifeMD amends Cleared Technologies acquisition; purchase price reduced to $3.67M with quarterly payments.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price reduced by $250,000 to $3,670,000; all earn-out payments eliminated.","Remaining $3.21M payable in 5 quarterly installments of $642k each, starting Feb 6, 2023 through Jan 15, 2024.","Buyer may pay installments in cash or common stock (accredited investors, Section 4(a)(2) exemption).","Mutual release of claims related to indemnification escrow and certain breaches of the Agreement.","LifeMD to reimburse $10,000 for legal expenses within 5 business days of the effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346991,"accession_number":"0001493152-22-036130","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD appoints Kathleen E. Walsh to Board; grants 75,000 restricted shares and 37,500 stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen E. Walsh appointed to Board on Dec 15, 2022; she is President & CEO of Boston Medical Center.","Received 75,000 restricted shares (37,500 vest immediately, 37,500 vest in 2 years).","Also received option to purchase 37,500 shares, vesting in 2 years.","Will receive $6,000 per quarter as Board compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346990,"accession_number":"0001493152-22-031678","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD furnishes investor presentation materials; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated November 2022 furnished as Exhibit 99.1 under Item 7.01.","Company expects to use materials in discussions with investors and analysts.","No financial results, guidance, or operational changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363379,"accession_number":"0001493152-22-026343","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints former Louisiana Governor Bobby Jindal to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective September 14, 2022; Jindal is the 55th Governor of Louisiana and current Operating Adviser at Ares Private Equity Group.","Compensation includes 75,000 restricted shares (half vest immediately, half in 2 years), option to purchase 37,500 shares (vesting over 1 year), and $6,000 quarterly retainer.","Jindal also serves on boards of Hornbeck Offshore Services and U.S. Heart and Vascular, and previously on boards of WellCare, Granicus, and Cotton Holdings.","Company cites Jindal's healthcare policy background and operational expertise to help scale virtual care offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363378,"accession_number":"0001493152-22-025851","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"LifeMD dismisses Friedman LLP, engages Marcum LLP as auditor after Friedman-Marcum combination","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective September 8, 2022, Audit Committee dismissed Friedman LLP and engaged Marcum LLP as independent auditor for FY2022.","Friedman's reports for FY2020-2021 had no adverse opinions or modifications; no disagreements occurred.","The change follows Friedman's combination with Marcum effective September 1, 2022; Friedman became a Marcum subsidiary.","Friedman furnished a letter to the SEC agreeing with the disclosures; filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383172,"accession_number":"0001493152-22-017477","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"LifeMD shareholders approve 1.5M share increase to 2020 equity plan, elect seven directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to 2020 Equity Incentive Plan approved, increasing authorized shares by 1,500,000.","Shareholders elected seven directors: Justin Schreiber, Stefan Galluppi, Naveen Bhatia, Joseph DiTrolio, Roberto Simon, John Strawn, Bertrand Velge.","Ratification of Friedman LLP as independent auditor for fiscal 2022 was approved with 19,576,630 votes for.","Proposal 2 (plan amendment) received 9,513,806 votes for, 2,429,175 against, 266,010 abstentions, and 7,429,916 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400975,"accession_number":"0001493152-22-005094","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"LifeMD subsidiary WorkSimpli acquires resume-building software assets for $4M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["WorkSimpli Software, majority-owned by LifeMD, acquired resume-building software assets from East Fusion FZCO for $4M cash.","Seller gets quarterly payments equal to greater of 15% Net Profits or $62,500 for 2 years, min $500,000.","Purchase financed by LifeMD promissory note secured by guarantees from Fitzpatrick Consulting and Sean Fitzpatrick.","Acquisition closed on February 17, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400974,"accession_number":"0001493152-22-005087","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD furnishes February 2022 investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated February 2022 furnished under Regulation FD.","Presentation to be used in meetings with investors and analysts starting Feb 22, 2022.","No specific financial results or material events provided in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400973,"accession_number":"0001493152-22-003384","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD appoints Maria Stan as Principal Accounting Officer, grants RSUs and PSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maria Stan appointed as Controller and Principal Accounting Officer effective Feb 4, 2022.","Stan has over 20 years of accounting and finance experience, previously served as Controller since March 2021.","Granted 15,000 RSUs vesting over 2 years and 50,000 performance share units tied to revenue, EBITDA, and stock price milestones.","Unvested awards are forfeited upon departure; full acceleration upon a Change of Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400972,"accession_number":"0001493152-22-002985","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeMD awards 75k RSUs and 250k PSUs to CFO; 37.5k RSUs and 105k PSUs to GC","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CFO Marc Benathen receives 75k RSUs vesting over 2 years and 250k PSUs tied to revenue/EBITDA/stock price milestones.","General Counsel Eric Yecies receives 37.5k RSUs vesting over 2 years and 105k PSUs with same performance criteria.","PSUs have a 5-year performance period; 100% accelerate upon Change of Control, forfeited on other departures.","Awards recognize 2021 contributions including Benathen's role in preferred share offering and Yecies' work on medical PC network."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400971,"accession_number":"0001493152-22-001561","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-01-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD furnishes investor presentation materials for January 2022","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished under Item 7.01, expected use starting January 20, 2022.","No specific financial results, guidance, or material new information in the filing.","Presentation available on LifeMD's website at https://lifemd.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400970,"accession_number":"0001493152-22-001552","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-01-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeMD reports FY2021 preliminary revenue of $92.9M, +149% YoY; FY2022 guidance $142-148M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2021 revenue $27.4M; FY2021 revenue $92.9M (149% YoY growth).","FY2022 revenue guidance $142-148M; Adj. EBITDA loss guidance ($14M)-($20M).","Q1 2022 revenue guidance $30-32M; Adj. EBITDA loss ($6.5M)-($7.5M).","Reaffirms Adj. EBITDA profitability target by Q4 2022.","Company highlights acquisition of Cleared and launch of LifeMD Virtual Primary Care Platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":92875806.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400969,"accession_number":"0001493152-22-001058","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"LifeMD acquires allergy telehealth platform Cleared; total consideration up to $76.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $460k cash + $3.46M milestone payments + up to $72.8M earn-out based on $150M revenue.","Acquisition expected to close in Q1 2022; Cleared provides allergy/asthma telehealth in all 50 states.","Deal expected to be accretive to LifeMD's Adjusted EBITDA in 2022 and significantly accretive thereafter.","LifeMD also purchasing a $507k convertible note from a strategic pharma investor alongside the acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419918,"accession_number":"0001493152-21-028044","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dr. Eleanor C. Mariano resigns from LifeMD board effective Nov 8, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Eleanor C. Mariano voluntarily resigned from the LifeMD board of directors effective November 8, 2021.","Resignation was not due to any disagreement with the company regarding operations, policies, or practices.","No replacement or further board changes were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419917,"accession_number":"0001493152-21-024517","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"LifeMD raises $21.4M from common, $32.9M from preferred stock offerings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3.83M common shares sold at $6.00/share; net proceeds ~$21.4M; $5M used to repay debt.","1.4M shares of 8.875% Series A Cumulative Perpetual Preferred at $25.00/share; net ~$32.9M.","Series A Preferred pays 8.875% cumulative quarterly dividends on $25.00 liquidation preference.","Proceeds to repay debt, fund dividend account, and for patient acquisition and acquisitions.","Both offerings closed Oct 4, 2021; underwriters' option exercised in full for common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437488,"accession_number":"0001493152-21-023872","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2021-09-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD furnishes investor presentation; no specific metrics in available text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation materials dated September 27, 2021, furnished under Regulation FD.","Intended for use in meetings with investors and analysts.","No specific financial data, guidance, or operational updates provided in the filing excerpt.","Company disclaims admission of materiality for the furnished information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437487,"accession_number":"0001493152-21-023338","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2021-09-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LifeMD files investor presentation under Regulation FD; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnishes investor presentation materials for use in meetings with investors and analysts commencing September 22, 2021.","Presentation is also available on the company's website at lifemd.com.","Filing does not contain any specific financial updates or operational metrics.","No forward-looking statements or guidance provided beyond general cautionary notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437486,"accession_number":"0001493152-21-022552","cik":948320,"company_name":"LifeMD, Inc.","ticker":"LFMD","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LifeMD appoints Naveen Bhatia to board as Happy Walters resigns; Bhatia gets 8,000 RSUs and 100,000 options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Happy Walters resigned from LifeMD board on September 8, 2021.","Naveen Bhatia appointed to board; he is a former Senior Director at Blackstone Tactical Opportunities Group.","Bhatia receives one-time grant of 8,000 RSUs vesting quarterly beginning September 30, 2021.","Bhatia also enters one-year consulting agreement: option to purchase 100,000 shares at $7.07 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":221016661.6462264,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-13T23:59:59+00:00|437486"}